首次人体间充质干细胞治疗放射性口干症(MESRIX):随机对照试验研究方案
这是一项单中心、I/II期、随机、安慰剂对照、双盲临床试验,计划纳入30例头颈癌放疗后口干症患者,按1:1随机接受超声引导下颌下腺注射脂肪来源间充质干细胞(ASC)或安慰剂。主要结局为非刺激全唾液流率变化,次要结局包括安全性、疗效、生活质量、唾液定性与定量测量以及基于对比剂增强MRI和粗针活检的颌下腺大小、血管化、纤维化和分泌组织评估。这是首次在放射性口干症患者中评估ASC安全性和疗效的尝试。
要点
- 单中心I/II期随机双盲安慰剂对照试验,30例患者按1:1随机分组。
- 干预为超声引导下颌下腺注射脂肪来源间充质干细胞或安慰剂。
- 主要结局为非刺激全唾液流率变化,评估时间点为基线及干预后1个月和4个月。
核心结论
- 该试验是首次评估脂肪来源间充质干细胞(ASC)在放射性口干症患者中安全性和疗效的尝试。
- 结果可能为ASC在唾液腺功能减退和口干症患者中的有效性提供证据,并为后续试验设计提供有价值的信息。
研究设计与样本
- 单中心、I/II期、随机、安慰剂对照、双盲临床试验。
- 共30例患者按1:1比例随机接受超声引导下颌下腺注射ASC或安慰剂。
- 评估在基线(治疗前1个月)以及研究干预后1个月和4个月进行。
主要发现
- 主要结局为非刺激全唾液流率变化。
- 次要结局包括安全性、疗效、生活质量变化、唾液定性与定量测量,以及基于对比剂增强磁共振成像(MRI)和粗针样本的颌下腺大小、血管化、纤维化和分泌组织评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salivary gland hypofunction and xerostomia are major complications following radiotherapy for head and neck cancer and may lead to debilitating oral disorders and impaired quality of life. Currently, only symptomatic treatment is available. However, mesenchymal stem cell (MSC) therapy has shown promising results in preclinical studies. Objectives are to assess safety and efficacy in a first-in-man trial on adipose-derived MSC therapy (ASC) for radiation-induced xerostomia. METHODS: This is a single-center, phase I/II, randomized, placebo-controlled, double-blinded clinical trial. A total of 30 patients are randomized in a 1:1 ratio to receive ultrasound-guided, administered ASC or placebo to the submandibular glands. The primary outcome is change in unstimulated whole salivary flow rate. The secondary outcomes are safety, efficacy, change in quality of life, qualitative and quantitative measurements of saliva, as well as submandibular gland size, vascularization, fibrosis, and secretory tissue evaluation based on contrast-induced magnetic resonance imaging (MRI) and core-needle samples. The assessments are performed at baseline (1 month prior to treatment) and 1 and 4 months following investigational intervention. DISCUSSION: The trial is the first attempt to evaluate the safety and efficacy of adipose-derived MSCs (ASCs) in patients with radiation-induced xerostomia. The results may provide evidence for the effectiveness of ASC in patients with salivary gland hypofunction and xerostomia and deliver valuable information for the design of subsequent trials. TRIAL REGISTRATION: EudraCT, Identifier: 2014-004349-29. Registered on 1 April 2015. ClinicalTrials.gov, Identifier: NCT02513238 . First received on 2 July 2015. The trial is prospectively registered.
引用
- Grønhøj C, Jensen DH, Glovinski PV, et al. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28270226. doi:10.1186/s13063-017-1856-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。